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SUMMARY
Introduction:  The burden of MDR-TB is unknown in 
areas that do not have drug susceptibility testing 
(DST), but its frequency is expected to be higher in 
previously treated cases.  Where DST is not available 
the WHO recommended standardized retreatment (Cat-
egory II) regimen is given to previously treated TB 
patients
Objective:  To evaluate the frequency and pattern of 
drug resistance of Mycobacterium tuberculosis isolated 
from patients with chronic smear positive pulmonary 
tuberculosis.
Method:  We conducted a retrospective review of my-
cobacterial cultures and drug susceptibility testing 
(DST) performed on sputum samples collected, be-
tween January 2005 and September 2006, from 40 pa-
tients with pulmonary TB who had failed at least one 
standard retreatment regimen.  Clinical data was ex-
tracted from patients’ case notes.
Results:  M. tuberculosis was recovered from 28 (70%) 
of the 40 patients.  Of the 28 culture positive cases, 10 
(36%) had resistance to at least rifampicin and isonia-
zid (multi-drug resistant TB), 22 (79%) isolates had 
resistance to streptomycin and 13 (46%) to ethambutol.  
Of the patients with a positive culture, only one (3.6%)
had a fully susceptible organism.    Of the 10 patients 
with MDR TB, 7 had received two or more retreatment 
courses.
Conclusion:  The frequency of drug resistant TB was 
high among patients who failed at least one course of 
category II therapy.  Effective combination regimens 
based on DST is necessary in patients who remain 
smear positive on the standardized retreatment regi-
men.
Keywords: drug-resistance, MDR, chronic TB, re-
treatment regimen.
INTRODUCTION
Drug resistant tuberculosis (TB), particularly multidrug 
resistant (MDR) represents a major global public health 
problem.  Several studies have found that MDR TB is 
associated with a higher risk of treatment failure and 
death.1-6  Based on data from 184 countries, it was es-
timated that 4.3% of all reported TB cases and 18.5% 
of previously treated cases in 2004 were MDR.7    In 
areas where drug susceptibility testing (DST) is not 
available, a standardized  retreatment (category II) reg-
imen is recommended for previously treated TB pa-
tients.8  This regimen consists of streptomycin (S), ri-
fampicin (R), isoniazid (I), pyrazinamide and ethambu-
tol (E) for two months, followed by one month of the 
same drugs except for streptomycin and then five 
months of rifampicin, isoniazid, and ethambutol 
(2SRHZE-1RHZE-5HRE). 
Countries in South America and Sub-Saharan Africa 
that have well organized DOTS programmes have a 
prevalence of chronic TB (defined as a case that re-
mains sputum positive at the end of a supervised stand-
ard retreatment regimen) is estimated at < 2%. 8, 9 Ad-
herent patients who remain smear positive at the end of 
the standard retreatment regimen are likely to have 
MDR TB and would need second-line drugs.  In 2006 
Green Light Committee (GLC) projects treated less 
than 5% of MDR-TB cases that emerged world-wide, 
and by the end of 2007 only 51 countries had been pro-
vided with second-line anti-TB drugs through the 
GLC.10   
In areas that do not have second-line drugs, the main 
option available to persons who have failed a standard 
treatment regimen is often a repeat of the same Catego-
ry II regimen.  This suboptimal approach to the man-
agement of chronic smear positive cases poses a signif-
icant transmission risk of resistant TB to close contacts 
and health care workers who provide care for these 
patients.  
Repeating Category II treatment after failure of a su-
pervised retreatment regimen is likely to increase the 
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degree and spectrum of drug resistance to first line 
drugs.  
Patients who had failed at least one previous treatment 
(the total number of ‘retreatment cases’) in Ghana in 
2006 were 526 (about 5% of all TB patients), of which 
the majority were due to relapse/failure and about 10% 
of these were defaulters (National TB Program re-
ports).  There were 56 patients on retreatment at the 
Chest Clinic in 2005 and 2006, and chronic TB cases 
would be a small proportion of this. Outcomes in these 
patients from Chest Clinic were; about 50% cure, 12.5 
% failure/relapse, 12.5% default and 25% mortality. 
The Chest Clinic laboratory in Korle Bu Teaching 
Hospital, the tertiary referral hospital for southern 
Ghana, was the only laboratory under the Ghana Health 
Service/Ministry of Health performing mycobacterial 
cultures in the southern half of Ghana in that period.  
Sufficient information had been sent out by the Nation-
al TB Program on the availability of the mycobacterial 
culture service and most DOTS centres in the region 
referred their chronic patients to Chest clinic for this 
reason.  In this review, we evaluated the frequency and 
pattern of drug resistance of Mycobacterium tuberculo-
sis isolated from patients with chronic smear positive 
pulmonary tuberculosis, who remained smear and cul-
ture positive for acid-fast bacilli (AFB) at the end of 
one or more courses of standard retreatment (Category 
II) therapy.
METHOD
The culture results of all chronic TB cases (had failed 
at least one retreatment course) referred to the Korle-
Bu Teaching Hospital Chest Clinic laboratory, repre-
senting a sample of chronic cases from the south of 
Ghana were  reviewed.  As the number of chronic cases 
in the country was small all patients who fitted the def-
inition of chronic TB were included in the study.  A
retrospective review was carried out over a period of 
21 months, from January 2005 to September 2006, of 
consecutive patients referred to the Chest Clinic labora-
tory who had a positive sputum smear test, having 
failed at least one retreatment course. Patients’ case 
notes were retrieved for information on number of re-
treatments, HIV status and outcomes.  HIV screening, 
not available in the Chest Clinic, was done at the Pub-
lic Health Reference Laboratory in Korle Bu. 
Counselling and HIV screening of TB patients was 
selective, based on clinical suspicion of HIV and pa-
tients’ willingness to be tested. Sputum samples from 
33 consecutive patients were received, with six of the 
33 patients re-entered into the study as their sputums 
were re-cultured within the study period, after failing
further retreatment courses.  Two samples, one spot 
and an early morning sample, were pooled and pre-
treated with 1% Cetylpyridinium Chloride (CPC) to 
inhibit the growth of fungi and other bacteria present.  
All samples were smear positive by Zeihl-Neelsen 
staining for AFB. Liquefaction and decontamination 
was carried out with the modified Petroff method.11  
The specimen was innoculated onto 3 Lowenstein-
Jensen (LJ) slopes containing 0.5% pyruvate, glycerol 
and PNB (p-nitrobenzoic acid 500 mg/l), and were 
incubated at 37 °C for up to 8 weeks.  Mycobacterium 
tuberculosis was confirmed by colony morphology, 
absence of pigment and failure to grow in PNB.  My-
cobacteria-other than TB (MOTT) were identified by 
rapid growth within 7 days and growth in PNB.12
Positive M. tuberculosis cultures were sub-cultured, 
and susceptibility testing to isoniazid, rifampicin, strep-
tomycin and ethambutol was performed by the simpli-
fied proportion method.13 The critical concentrations of 
the drugs were as follows: isoniazid 0.2 mg/l, rifampic-
in 40 mg/l, streptomycin 4.0 mg/l, and ethambutol 2.0 
mg/l.  The threshold proportion for resistance was 1% 
for all drugs.  A standard H37Rv strain of known re-
sistance to the drugs tested was used as controls in each 
batch of tests.  
RESULTS
Forty smear positive sputum samples were cultured of 
which 28 (70.0%) grew M. tuberculosis, 8 (20%) 
showed no bacterial growth, 3 had fungal contamina-
tion and one grew MOTT (a fast grower).  The median 
age for all patients was 38.8 years with ages ranging 
between 9 and 75 years.  Majority (71.4%) were male 
patients and were in the productive age group 25 to 64 
years.  The characteristics of the 28 patients with posi-
tive culture are shown in Table 1.  
Table 1 Demographic characteristics of 28 culture 
positive chronic TB patients 
CHARACTERISTIC
Age (yrs)
            Mean age 39.5 (SD 15.5 )
            Median 38




         Chest Clinic & Accra 22
          Other 6
HIV status
          Positive 3
          Negative 7
          Not Done 12
       Not Available 6
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Table 2 Frequency of drug resistance among 28 cul-





MDR (H+R) 10 35.71%
MDR + S 7 25.00%
MDR + E 6 21.43%
Panresistant (to SHR&E) 5 17.86%
Ethambutol 13 46.43%
H alone 6 21.43%
R alone 5 17.86%
Pansensitive 1 3.57%
Total Resistant TB strains 28
Majority of patients were being managed at Chest Clin-
ic, 3 were from other hospitals and clinics in Accra.  
Six whose records could not be traced were not Chest 
Clinic patients and had had cultures requested from 
DOTS centres in Tema and the Central Region, with 
one from the Ashanti Region.  
Data obtained from 22 case notes showed that 6 pa-
tients had relapsed after being declared cured, 11 were 
failures of one or more retreatments, and 8 had a histo-
ry of default, 3 being recurrent defaulters.  The mean 
number of treatment courses they had had was 2.9, 
majority having had 2 or more retreatment courses
Twelve patients had not had their HIV status deter-
mined, 3 others were HIV positive and 7 HIV negative.  
The results of DST are shown in Table 2. Of the 28 
patients, 10 (36%) had MDR-TB, 6 (21%) had isonia-
zid mono resistance and 5 (18%) had rifampicin mono 
resistance.  
Figure 2 Frequency of Drug Resistant- and MDR- TB 
in relation to number of retreatment (RTR) regimens
Overall, 79% had resistance to streptomycin, 18% had 
resistance to all four drugs and only one patient (3.6%) 
had an isolate susceptible to all 4 drugs.  The preva-
lence of mono- and multiple-drug resistance patterns 
are shown in a Venn diagram (Figure 1).
Four out of 8 defaulters (50%) and 4 out of 6 with re-
lapse-after-cure (66.6%) had MDR-TB.  The propor-
tions with mono- or multi-drug resistance in relation to 
the number of retreatments a patient had showed an 
increasing trend for rifampicin resistance and MDR, 
though significance could not be determined because of 
insufficient patient numbers (Figure 2).
                     46% Ethambutol
               (n=13)
MDR 
36%
                  
   79%                   
Streptomycin
     (n=22)
(n=10)
Figure 1 Pattern of Drug Resistance among 28 culture positive patients
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DISCUSSION
Tuberculosis had a world-wide incidence of 9 million 
people in 2006, and nearly 1.7 million people die every 
year from TB.8, 14 Combination therapy with effective 
anti-tuberciulosis agents is intended to improve cure 
rates and prevent the emergence of drug resistance.  
Resistance to the antituberculosis drugs is being recog-
nized more and more as their effectiveness is subverted 
by poor adherence, inadequate dosing and prescription 
of incorrect regimens, effectively exposing organisms 
to monotherapy. 15   As developing countries acquire the 
expertise and the resources required to diagnose it re-
sistant tuberculosis is being recognized more and more.  
While a few drug resistance surveys have been carried 
out on primary TB isolates from treatment-naïve pa-
tients in Ghana, only one has studied previously treated
patients.  Newman MJ et al. in a previous survey of 
chronic TB patients in this teaching hospital reported a 
high level of resistance among 18 cultured isolates, 
with 15 (83%) showing resistance to at least two first-
line anti-tuberculosis drugs.16 Thirty-three percent 
(33%) were MDR which was similar to our review, 
however only 3.6% in our review were pan-sensitive to 
all drugs, compared with 16.7% in Newman’s study, 
who were likely to respond to further first-line treat-
ment. A well performing DOTS program is the best 
prevention against chronic disease and MDR-TB.  In 
developing countries that have had a well applied 
DOTS strategy for several years, chronic cases repre-
sent less than 2% of the total smear-positive pulmonary 
TB cases.9,10   
In a Peruvian study on mycobacterial culture and DST 
of pulmonary TB cases 18% of cases were MDR-TB, 
which accounted for 71% of deaths in both HIV posi-
tive and negative patients.3 High levels of drug re-
sistance among our chronic TB patients represents a 
risk for likely transmission of resistant strains to sus-
ceptible persons in the community as well as an in-
creased mortality on standard drug therapy.  A 2000-
2004 survey of primary anti-TB drug resistance in 
Ghana on 2,064 isolates, reported then a high level of 
initial Streptomycin resistance of 23% in treatment-
naïve patients.17 The even higher prevalence of re-
sistance to streptomycin in the present study (79%) 
means the recommended WHO retreatment regimen 
which is routinely given in the absence of DST will not 
be effective and may even create greater resistance to 
the essential drugs in use as it fails to add on any effec-
tive new drug to the Category I regimen.  Among the 
28 positive cultures drug resistant TB was present in all 
groups irrespective of whether they had had one, two 
or three retreatments.  This was particularly so with 
streptomycin and isoniazid, while rifampicin and MDR 
resistance appeared to be more common in patients 
who had completed three retreatments.  We could not 
establish the significance of this trend given the small 
numbers of patients studied.  
However the observed trend is what one would expect 
from the natural history of resistance development, 15
and has been demonstrated in a large cohort in Uganda. 
18 Some authors have reported that even in the settings 
of moderate rates of MDR-TB, DOTS using only first-
line drugs can be effective and reduce the transmission 
of both drug-susceptible and drug-resistant TB,2 but 
others have found DOTS alone to be inadequate in 
patients with drug-resistant TB.1,14,19  Urgent considera-
tion is needed for the use of a standardized Category 
IV regimen combining effective first line drugs with 
selected second line drugs (including an injectable) for 
MDR, present in over a third of our chronic TB pa-
tients. 
This has been feasible in other resource-limited coun-
tries with an efficient NTP, and has been demonstrated 
to be cost effective in Peru.9, 20    A major limitation of 
this study is the small number of chronic TB cases in-
cluded in this report.  Thus, the results should be inter-
preted with caution.    This was a new laboratory ser-
vice and selection bias could have occurred as some 
practitioners may not have been aware of the availabil-
ity of mycobacterial culture or just did not have their 
chronic patients’ sputum cultured in spite of repeated 
failures.  The results of this review suggest that more 
studies on M. tuberculosis resistance are required,
which will give support to the strengthening of the Na-
tional TB Program, for application to the Green Light 
Committee for second line drugs.
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